Study on the usefulness of novel excision repair cross-complementation group-1 (ERCC-1) antibody for predicting the therapeutic effect of FOLFIRINOX therapy for pancreatic cancer
Not Applicable
Recruiting
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000045997
- Lead Sponsor
- agasaki University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
none
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Ratio of new anti-ERCC-1 antibody and conventional anti-ERCC-1 antibody immunohistochemical staining in surgical specimens 2. Correlation between the expression level of anti-ERCC-1 antibody and ERCC1 RNA in surgical specimens
- Secondary Outcome Measures
Name Time Method